These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31310287)

  • 1. Price Increases of Protected-Class Drugs in Medicare Part D, Relative to Inflation, 2012-2017.
    Hwang TJ; Dusetzina SB; Feng J; Maini L; Kesselheim AS
    JAMA; 2019 Jul; 322(3):267-269. PubMed ID: 31310287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases.
    Dickson S
    JAMA Netw Open; 2020 Sep; 3(9):e2016388. PubMed ID: 32915237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Medicare Part D on Pharmaceutical Prices and Utilization.
    Duggan M; Morton FS
    Am Econ Rev; 2010 Mar; 100(1):590-607. PubMed ID: 29508975
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
    Blumberg DM; Prager AJ; Liebmann JM
    JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescription Drugs-List Price, Net Price, and the Rebate Caught in the Middle.
    Dusetzina SB; Bach PB
    JAMA; 2019 Apr; 321(16):1563-1564. PubMed ID: 30840047
    [No Abstract]   [Full Text] [Related]  

  • 7. Specialty pharmacy management will become more intense.
    Collins S
    Manag Care; 2010 Oct; 19(10):20-3. PubMed ID: 21049783
    [No Abstract]   [Full Text] [Related]  

  • 8. Providing prescription drug coverage to the elderly: America's experiment with Medicare Part D.
    Duggan M; Healy P; Morton FS
    J Econ Perspect; 2008; 22(4):69-92. PubMed ID: 19768843
    [No Abstract]   [Full Text] [Related]  

  • 9. Medicare Part D Protected-Class Policy Is Associated With Lower Drug Rebates.
    Kakani P; Kyle MA; Chandra A; Maini L
    Health Aff (Millwood); 2024 Oct; 43(10):1420-1427. PubMed ID: 39374459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicare Part D update--lessons learned and unfinished business.
    Neuman P; Cubanski J
    N Engl J Med; 2009 Jul; 361(4):406-14. PubMed ID: 19625722
    [No Abstract]   [Full Text] [Related]  

  • 11. Digesting the doughnut hole.
    Joyce GF; Zissimopoulos J; Goldman DP
    J Health Econ; 2013 Dec; 32(6):1345-55. PubMed ID: 24308883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Encouraging generic use can yield significant savings.
    Zimmerman C
    Find Brief; 2012 Nov; 15(8):1-3. PubMed ID: 23213854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Top 40 Medicare Part D prescription drugs Ranked by total payments in 2014.
    Mod Healthc; 2016 Oct; 46(36):42. PubMed ID: 30398720
    [No Abstract]   [Full Text] [Related]  

  • 14. Beneficiary price sensitivity in the Medicare prescription drug plan market.
    Frakt AB; Pizer SD
    Health Econ; 2010 Jan; 19(1):88-100. PubMed ID: 19191252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceuticals and medical devices: Medicare Part D.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-37. PubMed ID: 22403844
    [No Abstract]   [Full Text] [Related]  

  • 16. Favorable Formulary Placement of Branded Drugs in Medicare Prescription Drug Plans When Generics Are Available.
    Socal MP; Bai G; Anderson GF
    JAMA Intern Med; 2019 Jun; 179(6):832-833. PubMed ID: 30882842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A New Safe Harbor - Turning Drug Rebates into Discounts in Medicare Part D.
    Gellad WF; Ennis M; Kuza CC
    N Engl J Med; 2019 May; 380(18):1688-1690. PubMed ID: 30946552
    [No Abstract]   [Full Text] [Related]  

  • 18. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
    Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
    Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doughnuts and Discounts - Changes to Medicare Part D under the Bipartisan Budget Act of 2018.
    Donohue JM; Huskamp HA
    N Engl J Med; 2018 May; 378(21):1957-1960. PubMed ID: 29791823
    [No Abstract]   [Full Text] [Related]  

  • 20. Demand for prescription drugs under non-linear pricing in Medicare Part D.
    Jung K; Feldman R; McBean AM
    Int J Health Care Finance Econ; 2014 Mar; 14(1):19-40. PubMed ID: 24214101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.